Studies related to Cancer Pain (Various) and Cannabis

An Open-label Extension Study To Investigate The Long-term Safety And Tolerability Of THC/CBD Oromucosal Spray And Oromucosal THC Spray In Patients With Terminal Cancer-related Pain Refractory To Strong Opioid Analgesics

Effect Decrease
Trial Design Non-controlled trial
Trial Length 1-6 months
Number of Subjects 39
Sex Both Genders
Notes for this study:
In an open-label study, 39 participants with cancer-related pain refractory to opioid analgesics took a THC/CBD spray that delivered 2.7 mg of THC and 2.5 mg of CBD per 100 ul spray. Participants decided on their own doses but could use a maximum of 48 sprays per 24-hour period or 50% higher than the previous day's dose. The median duration of treatment was 25 days with a minimum of two and maximum of 579.

The primary outcome was pain on the Brief Pain Inventory Short Form and pain notably declined throughout 5 weeks.
Funding issues for this study:
This study was sponsored by GW Pharma
Ltd. The authors confirm that there were no
conflicts of interest in this study. J. R. Johnson,
D. Lossignol, J. Hardy, M. Burnell-Nugent, I.
Trotman, M. Leng and M. T. Fallon were all investigators in this study and their institutions
received investigator fees from GW Pharma
Ltd. accordingly for their participation in the
study.

Full details on all 5 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.